Last reviewed · How we verify
Ferric Pyrophosphate Liposomal
Ferric pyrophosphate encapsulated in liposomes delivers iron in a bioavailable form to treat iron deficiency by replenishing systemic iron stores.
Ferric pyrophosphate encapsulated in liposomes delivers iron in a bioavailable form to treat iron deficiency by replenishing systemic iron stores. Used for Iron deficiency anemia.
At a glance
| Generic name | Ferric Pyrophosphate Liposomal |
|---|---|
| Also known as | liposomal iron, Novoferr |
| Sponsor | All India Institute of Medical Sciences |
| Drug class | Iron supplement |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
The liposomal formulation protects ferric pyrophosphate from degradation in the gastrointestinal tract and enhances absorption through the intestinal epithelium. This allows for improved bioavailability and reduced gastrointestinal side effects compared to conventional iron supplements. The iron is then incorporated into hemoglobin and other iron-dependent proteins to restore normal oxygen-carrying capacity and metabolic function.
Approved indications
- Iron deficiency anemia
Common side effects
- Gastrointestinal disturbance
- Constipation
- Nausea
Key clinical trials
- A Study to Compare Liposomal Iron With Ferrous Ascorbate in the Treatment of Iron Deficiency Anemia in Children (PHASE3)
- Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children (PHASE4)
- Tolerability of Iron Therapy in Women With AUB
- Anemia in Inflammatory Bowel Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: